摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

顺式-1,3-二乙酰氧基环己烷 | 832-09-7

中文名称
顺式-1,3-二乙酰氧基环己烷
中文别名
——
英文名称
cis-1.3-Diacetoxy-cyclohexan
英文别名
cis-1,3-Diacetoxycyclohexane;[(1S,3R)-3-acetyloxycyclohexyl] acetate
顺式-1,3-二乙酰氧基环己烷化学式
CAS
832-09-7
化学式
C10H16O4
mdl
——
分子量
200.235
InChiKey
PIAZUOCNDRREHF-AOOOYVTPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    249.7±33.0 °C(Predicted)
  • 密度:
    1.09±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    52.6
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2915390090

SDS

SDS:36c68068e2eec7ff4cb5af86486693d4
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Rhodium(I)-catalyzed hydroboration of olefins. The documentation of regio- and stereochemical control in cyclic and acyclic systems
    作者:David A. Evans、Gregory C. Fu、Amir H. Hoveyda
    DOI:10.1021/ja00228a068
    日期:1988.9
    Catalyse par les complexes Rh(PPh 3 ) 3 Cl et [Rh(nbd)(diphos-4)]BF 4 (nbd=norbornadiene, diphos-4=bis-diphenylphosphino-1,4 butane)
    催化复合物 Rh(PPh 3 ) 3 Cl et [Rh(nbd)(diphos-4)]BF 4 (nbd=降冰片二烯,diphos-4=双-二苯基膦基-1,4丁烷)
  • Rhodium(I)- and iridium(I)-catalyzed hydroboration reactions: scope and synthetic applications
    作者:David A. Evans、Gregory C. Fu、Amir H. Hoveyda
    DOI:10.1021/ja00043a009
    日期:1992.8
    A study of the rhodium(1)- and iridium(1)-catalyzed hydroboration of olefins with catecholborane is described. Applications to organic synthesis were one focus of this investigation. The scope of the reaction was defined, and issues of stereoselection were addressed. The rhodium-catalyzed hydroboration of several classes of allylic alcohols was found to be highly diastereoselective, preferentially
    描述了 (1)-和 (1)-催化烯烃与儿茶酚硼烷氢化的研究。有机合成的应用是这项研究的重点之一。定义了反应的范围,并解决了立体选择问题。发现几类烯丙醇催化氢化反应具有高度的非对映选择性,优先提供与未催化反应变体 (9-BBN) 提供的异构体互补的异构体。开发了实现定向烯烃氢化的前两种通用方法。亚膦酸盐和酰胺都证明能够传递过渡属试剂。
  • METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES
    申请人:Salagnad Christophe
    公开号:US20070197614A1
    公开(公告)日:2007-08-23
    The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.
    本发明涉及一种制备公式(I)的二芳基环烷基衍生物的方法,其中各自的R基取代基如本文所定义。公式(I)化合物是过氧化物酶体增殖物激活受体(PPAR激活剂),在治疗多发性硬化症、帕森病、精神障碍等中枢神经系统疾病和疾病方面非常有用。本发明提供了一种新的制备公式(I)的PPAR激活剂的方法,该方法不具有先前技术中已知的缺点。特别是,提供了一种方法,可以在不需要后续手性色谱的情况下以适当的对映选择性制备公式(I)的PPAR激活剂,即高对映选择性。
  • NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES
    申请人:Salagnad Christophe
    公开号:US20080051583A1
    公开(公告)日:2008-02-28
    The invention relates generally to intermediate compounds derived during the process for preparing diarylcycloalkyl derivatives which are activators for peroxisome proliferator-activated receptors (PPAR activators) and are therefore useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The intermediate compounds of the present invention are defined structurally by the formulae (Ia): and formula (II): wherein the respective substituent groups are defined herein.
    本发明涉及制备二苯基环烷衍生物的过程中产生的中间化合物,该化合物是过氧化物酶体增殖物活化受体(PPAR活化剂),因此在治疗多发性硬化症、帕森病、精神障碍等中枢神经系统疾病和疾病方面具有用处。本发明的中间化合物在结构上由公式(Ia)和公式(II)定义,其中各取代基在此定义。
  • Method for the production of diarylcycloalkyl derivatives
    申请人:Sanofi-Aventis Deutschland GmbH
    公开号:US07803950B2
    公开(公告)日:2010-09-28
    The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.
    本发明涉及一种制备公式(I)的二芳基环烷基衍生物的过程,其中各自的R基取代基在此定义。这些公式(I)化合物是过氧化物酶体增殖物激活受体(PPAR激活剂),可用于治疗中枢神经系统的多种疾病和障碍,如多发性硬化症,帕森病,精神障碍等。本发明是一种新型制备公式(I)的PPAR激活剂的过程,其不具有先前技术中已知的缺点。特别是,提供了一种方法,可以在不需要后续手性色谱的情况下制备公式(I)的PPAR激活剂,即高对映选择性,以适当的对映异构体过量。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸